ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).

상세 보기

Citations

WEB OF SCIENCE

0

제목: ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).

저자: Lim, Sung Hee; Nakayama, Izuma; Ryu, Min-Hee; Kim, Jong Gwang; Omori, Takeshi; Oh, Sang Cheul; Kim, Jin Young; Rha, Sun Young; Lee, Keun-Wook; Machida, Nozomu; Sym, Sun Jin; Narita, Yukiya; Park, Young-Iee; Hara, Hiroki; Hosaka, Hisashi; Kang, Beodeul; Kim, In-Ho; Bai, Li-Yuan; Shitara, Kohei